Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Retraction: Sensitizing Estrogen Receptor-negative Breast Cancer Cells to Tamoxifen with OSU-03012, a Novel Celecoxib-derived Phosphoinositide-dependent Protein Kinase-1/Akt Signaling Inhibitor.

Weng SC, Kashida Y, Kulp SK, Wang D, Brueggemeier RW, Shapiro CL, Chen CS.

Mol Cancer Ther. 2019 Apr;18(4):869. doi: 10.1158/1535-7163.MCT-19-0151. No abstract available.

PMID:
30936413
2.

Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.

Sugimoto Y, Sawant DB, Fisk HA, Mao L, Li C, Chettiar S, Li PK, Darby MV, Brueggemeier RW.

Bioorg Med Chem. 2017 Apr 1;25(7):2156-2166. doi: 10.1016/j.bmc.2017.02.030. Epub 2017 Feb 16.

PMID:
28259529
3.

Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.

Eloy JO, Petrilli R, Brueggemeier RW, Marchetti JM, Lee RJ.

Anticancer Agents Med Chem. 2017;17(1):48-56.

4.

Oncolytic potential of a novel KGFR tyrosine kinase inhibitor using a KGFR-selective breast cancer xenograft model.

Kesinger JW, Mehta M, Lerner MR, Brackett DJ, Brueggemeier RW, Li PK, Pento JT.

Anticancer Res. 2015 Jan;35(1):47-52.

PMID:
25550534
5.

Maintaining pharmacy education's research focus as the academy expands.

Bauman JL, Ascione FJ, Brueggemeier RW, Letendre DE, Roberts JC, Speedie MK, Svensson CK.

Am J Pharm Educ. 2012 Oct 12;76(8):144. doi: 10.5688/ajpe768144. No abstract available.

6.

Are we producing innovators and leaders or change resisters and followers?

Svensson CK, Ascione FJ, Bauman JL, Brueggemeier RW, Letendre DE, Roberts JC, Speedie MK.

Am J Pharm Educ. 2012 Sep 10;76(7):124. doi: 10.5688/ajpe767124. No abstract available.

7.

Highly efficient cationic ethylphosphatidylcholine siRNA carrier for GFP suppression in modified breast cancer cells.

Tenchov B, Sugimoto Y, Koynova R, Brueggemeier RW, Lee RJ.

Anticancer Res. 2012 Jul;32(7):2563-6.

8.

Human serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer.

Piao L, Li H, Teng L, Yung BC, Sugimoto Y, Brueggemeier RW, Lee RJ.

Nanomedicine. 2013 Jan;9(1):122-9. doi: 10.1016/j.nano.2012.03.008. Epub 2012 Apr 26.

9.

Differential efficacy of DOTAP enantiomers for siRNA delivery in vitro.

Terp MC, Bauer F, Sugimoto Y, Yu B, Brueggemeier RW, Lee LJ, Lee RJ.

Int J Pharm. 2012 Jul 1;430(1-2):328-34. doi: 10.1016/j.ijpharm.2012.04.017. Epub 2012 Apr 15.

10.

The path forward: the future of graduate education in the pharmaceutical sciences: the report of the 2010-2011 Research and Graduate Affairs Committee.

Brueggemeier RW, Clark AM, Das SK, Forbes DS, Leff RD, Oie S, Sorofman BA, Thompson DF, Maine LL, Sagraves R.

Am J Pharm Educ. 2011 Dec 15;75(10):S13. doi: 10.5688/ajpe7510S13. No abstract available.

11.

SPANosomes as delivery vehicles for small interfering RNA (siRNA).

Zhou C, Mao Y, Sugimoto Y, Zhang Y, Kanthamneni N, Yu B, Brueggemeier RW, Lee LJ, Lee RJ.

Mol Pharm. 2012 Feb 6;9(2):201-10. doi: 10.1021/mp200426h. Epub 2011 Dec 29.

12.

Comparison of increased aromatase versus ERα in the generation of mammary hyperplasia and cancer.

Díaz-Cruz ES, Sugimoto Y, Gallicano GI, Brueggemeier RW, Furth PA.

Cancer Res. 2011 Aug 15;71(16):5477-87. doi: 10.1158/0008-5472.CAN-10-4652.

13.

Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.

Lustberg MB, Povoski SP, Zhao W, Ziegler RM, Sugimoto Y, Ruppert AS, Lehman AM, Shiels DR, Mrozek E, Ramaswamy B, Layman RM, Brueggemeier RW, Shapiro CL.

Clin Breast Cancer. 2011 Aug;11(4):221-7. doi: 10.1016/j.clbc.2011.03.022. Epub 2011 May 19.

14.

Reconsidering the length of program accreditation.

Svensson CK, Speedie MK, Roberts JC, Letendre DE, Brueggemeier RW, Bauman JL, Ascione FJ.

Am J Pharm Educ. 2011 Feb 10;75(1):6. No abstract available.

15.

Influence of novel KGFR tyrosine kinase inhibitors on KGF-mediated proliferation of breast cancer.

Mehta M, Kesinger JW, Zang XP, Lerner ML, Brackett DJ, Brueggemeier RW, Li PK, Pento JT.

Anticancer Res. 2010 Dec;30(12):4883-9.

PMID:
21187466
16.

Isolation and Characterization of Aromatase Inhibitors from Brassaiopsis glomerulata (Araliaceae).

Balunas MJ, Su B, Riswan S, Fong HH, Brueggemeier RW, Pezzuto JM, Kinghorn AD.

Phytochem Lett. 2009 Feb 19;2(1):29-33.

17.

Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells.

Zheng Y, Yu B, Weecharangsan W, Piao L, Darby M, Mao Y, Koynova R, Yang X, Li H, Xu S, Lee LJ, Sugimoto Y, Brueggemeier RW, Lee RJ.

Int J Pharm. 2010 May 10;390(2):234-41. doi: 10.1016/j.ijpharm.2010.02.008. Epub 2010 Feb 13.

18.

Selective regulation of aromatase expression for drug discovery.

Brueggemeier RW, Su B, Darby MV, Sugimoto Y.

J Steroid Biochem Mol Biol. 2010 Feb 28;118(4-5):207-10. doi: 10.1016/j.jsbmb.2009.11.009. Epub 2009 Dec 1.

19.

Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?

Miller WR, Bartlett J, Brodie AM, Brueggemeier RW, di Salle E, Lønning PE, Llombart A, Maass N, Maudelonde T, Sasano H, Goss PE.

Oncologist. 2008 Aug;13(8):829-37. doi: 10.1634/theoncologist.2008-0055. Epub 2008 Aug 11. Review.

20.

Natural products as aromatase inhibitors.

Balunas MJ, Su B, Brueggemeier RW, Kinghorn AD.

Anticancer Agents Med Chem. 2008 Aug;8(6):646-82. Review.

21.

Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity.

Balunas MJ, Su B, Brueggemeier RW, Kinghorn AD.

J Nat Prod. 2008 Jul;71(7):1161-6. doi: 10.1021/np8000255. Epub 2008 Jun 18.

22.

Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.

Weng SC, Kashida Y, Kulp SK, Wang D, Brueggemeier RW, Shapiro CL, Chen CS.

Mol Cancer Ther. 2008 Apr;7(4):800-8. doi: 10.1158/1535-7163.MCT-07-0434. Retraction in: Mol Cancer Ther. 2019 Apr;18(4):869.

23.

Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer.

Su B, Darby MV, Brueggemeier RW.

J Comb Chem. 2008 May-Jun;10(3):475-83. doi: 10.1021/cc700138n. Epub 2008 Apr 2.

24.

Novel sulfonanilide analogs decrease aromatase activity in breast cancer cells: synthesis, biological evaluation, and ligand-based pharmacophore identification.

Su B, Tian R, Darby MV, Brueggemeier RW.

J Med Chem. 2008 Mar 13;51(5):1126-35. doi: 10.1021/jm701107h. Epub 2008 Feb 14.

PMID:
18271519
25.

4-Hydroxyphenylretinamide (4HPR) derivatives regulate aromatase activity and expression in breast cancer cells.

Su B, Mershon SM, Stonerock LA, Curley RW Jr, Brueggemeier RW.

J Steroid Biochem Mol Biol. 2008 Mar;109(1-2):40-6. doi: 10.1016/j.jsbmb.2007.12.005. Epub 2007 Dec 7.

PMID:
18248980
26.

Development of keratinocyte growth factor receptor tyrosine kinase inhibitors for the treatment of cancer.

Hackett J, Xiao Z, Zang XP, Lerner ML, Brackett DJ, Brueggemeier RW, Li PK, Pento JT.

Anticancer Res. 2007 Nov-Dec;27(6B):3801-6.

27.
28.

Evaluation of synthetic isoflavones on cell proliferation, estrogen receptor binding affinity, and apoptosis in human breast cancer cells.

Davis DD, Díaz-Cruz ES, Landini S, Kim YW, Brueggemeier RW.

J Steroid Biochem Mol Biol. 2008 Jan;108(1-2):23-31. Epub 2007 Sep 7.

29.

Aromatase and COX in breast cancer: enzyme inhibitors and beyond.

Brueggemeier RW, Su B, Sugimoto Y, Díaz-Cruz ES, Davis DD.

J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):16-23. Epub 2007 May 25.

30.

Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells.

Su B, Landini S, Davis DD, Brueggemeier RW.

J Med Chem. 2007 Apr 5;50(7):1635-44. Epub 2007 Feb 22.

PMID:
17315855
31.

Update on the use of aromatase inhibitors in breast cancer.

Brueggemeier RW.

Expert Opin Pharmacother. 2006 Oct;7(14):1919-30. Review.

PMID:
17020418
32.

Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.

Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS.

Mol Pharmacol. 2006 Nov;70(5):1534-41. Epub 2006 Aug 3.

PMID:
16887935
33.

Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer.

Díaz-Cruz ES, Brueggemeier RW.

Anticancer Agents Med Chem. 2006 May;6(3):221-32. Review.

PMID:
16712450
34.

Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay.

Balunas MJ, Su B, Landini S, Brueggemeier RW, Kinghorn AD.

J Nat Prod. 2006 Apr;69(4):700-3.

PMID:
16643058
35.

Relationship between aromatase and cyclooxygenases in breast cancer: potential for new therapeutic approaches.

Brueggemeier RW, Díaz-Cruz ES.

Minerva Endocrinol. 2006 Mar;31(1):13-26. Review.

PMID:
16498361
36.

Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition.

Su B, Diaz-Cruz ES, Landini S, Brueggemeier RW.

J Med Chem. 2006 Feb 23;49(4):1413-9.

PMID:
16480277
37.

Lead optimization of 7-benzyloxy 2-(4'-pyridylmethyl)thio isoflavone aromatase inhibitors.

Su B, Hackett JC, Díaz-Cruz ES, Kim YW, Brueggemeier RW.

Bioorg Med Chem. 2005 Dec 1;13(23):6571-7. Epub 2005 Aug 24.

PMID:
16125392
38.

Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer.

Brueggemeier RW, Díaz-Cruz ES, Li PK, Sugimoto Y, Lin YC, Shapiro CL.

J Steroid Biochem Mol Biol. 2005 May;95(1-5):129-36.

PMID:
15964185
39.

Synthesis and characterization of azole isoflavone inhibitors of aromatase.

Hackett JC, Kim YW, Su B, Brueggemeier RW.

Bioorg Med Chem. 2005 Jun 2;13(12):4063-70. Epub 2005 Apr 25.

PMID:
15911319
40.

Aromatase inhibitors in the treatment of breast cancer.

Brueggemeier RW, Hackett JC, Diaz-Cruz ES.

Endocr Rev. 2005 May;26(3):331-45. Epub 2005 Apr 6. Review.

PMID:
15814851
41.

The final catalytic step of cytochrome p450 aromatase: a density functional theory study.

Hackett JC, Brueggemeier RW, Hadad CM.

J Am Chem Soc. 2005 Apr 13;127(14):5224-37.

PMID:
15810858
42.

Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells.

Díaz-Cruz ES, Shapiro CL, Brueggemeier RW.

J Clin Endocrinol Metab. 2005 May;90(5):2563-70. Epub 2005 Feb 1.

PMID:
15687328
43.

Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells.

Huang JW, Shiau CW, Yang YT, Kulp SK, Chen KF, Brueggemeier RW, Shapiro CL, Chen CS.

Mol Pharmacol. 2005 Apr;67(4):1342-8. Epub 2005 Jan 13.

PMID:
15653552
44.

Synthesis and aromatase inhibitory activity of novel pyridine-containing isoflavones.

Kim YW, Hackett JC, Brueggemeier RW.

J Med Chem. 2004 Jul 29;47(16):4032-40.

PMID:
15267241
45.

Aromatase inhibitors: new endocrine treatment of breast cancer.

Brueggemeier RW.

Semin Reprod Med. 2004 Feb;22(1):31-43. Review.

PMID:
15083379
46.

Aromatase and cyclooxygenases: enzymes in breast cancer.

Brueggemeier RW, Richards JA, Petrel TA.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):501-7. Review.

PMID:
14623550
47.

Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer.

Mobley JA, Brueggemeier RW.

Carcinogenesis. 2004 Jan;25(1):3-9. Epub 2003 Sep 26.

PMID:
14514655
48.
49.
50.

Supplemental Content

Loading ...
Support Center